- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Gilead Knew Sovaldi Price Was High
What we're reading, December 2, 2015: Gilead priced Sovaldi knowing the high cost would be a challenge for patients and payers; Senate Republicans will vote Thursday on Obamacare repeal and expect to get the needed votes; and a report calls for a better focus on women's health.
Gilead Priced Sovaldi High Despite Knowing Challenges It Would Cause
An investigation into Gilead Sciences Inc’s pricing of its hepatitis C drug Sovaldi revealed that the company knew the list price would cause payers to restrict patient access and would present challenges for government health programs. The Wall Street Journal also reported that the US Senate committee reviewing internal documents uncovered one executive vice president urged the company not to “fold to advocacy pressure” and to stick with the $1000-a-pill price tag no matter what the response was.
GOP Confident It Will Pass Obamacare Repeal
If Senate Republicans are to pass their Affordable Care Act repeal and send it to the president’s desk, they can only afford 3 Republicans to jump ship. Currently 2 appear likely to defect over provisions in the bill to defund Planned Parenthood, although Senate Republicans are confident they will secure the needed 51 votes by the vote on Thursday, reported Politico. However, Republicans from states that have expanded Medicaid may be concerned about passing the bill.
Task Force Report Identifies Needed Research in Women’s Health
The US Preventive Services Task Force has called for a focus on women’s health beyond gynecological and reproductive issues. The report identified 5 high priority areas where there is a gap in evidence-based research. These areas include addressing effective screening in women for issues of domestic violence, drug abuse, depression, and suicide; thyroid dysfunction; and how recommendations can be implemented in primary care practices.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
